Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519395 | 0.90 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL23212543 | 0.87 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL14800921 | 0.85 | ALDH1A1 (0.43) | L3MBTL1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL21523624 | 0.85 | L3MBTL1 (0.54) | L3MBTL1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL17607084 | 0.82 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL27028588 | 0.78 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL672209 | 0.78 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL27229343 | 0.77 | ALDH1A1 (0.41) | L3MBTL1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL1284747 | 0.75 | KMT2A (0.51) | L3MBTL1ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL1559387 | 0.75 | ALDH1A1 (0.39) | L3MBTL1ALDH1A1MAPTPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC | 2018-10-25 | — | — | US | disclosed |
| EP-3310776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2017-02-09 | — | — | US | disclosed |
| US-9518065-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518065-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-04-02 | — | — | US | disclosed |
| WO-2015048281-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | L3MBTL1 1168/4885ALDH1A1 4726/4885MAPT 4203/4885 |
| US-20170035766-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL1 549/4885ALDH1A1 4076/4885MAPT 1832/4885 |
| US-20150094305-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL1 549/4885ALDH1A1 4076/4885MAPT 1832/4885 |
| US-20180305348-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | L3MBTL1 1168/4885ALDH1A1 4726/4885MAPT 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.